Leonid Timashev
Stock Analyst at RBC Capital
(4.21)
# 456
Out of 5,111 analysts
134
Total ratings
53.33%
Success rate
14.1%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $87 → $95 | $61.73 | +53.90% | 5 | Dec 22, 2025 | |
| PYXS Pyxis Oncology | Maintains: Outperform | $8 → $5 | $1.15 | +334.78% | 7 | Dec 19, 2025 | |
| INSM Insmed | Maintains: Outperform | $215 → $195 | $177.12 | +10.09% | 7 | Dec 18, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $6 → $13 | $9.09 | +43.01% | 10 | Nov 20, 2025 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $395 → $408 | $311.02 | +31.18% | 5 | Nov 18, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $53 → $61 | $41.79 | +45.97% | 2 | Nov 17, 2025 | |
| LEGN Legend Biotech | Maintains: Outperform | $75 → $74 | $21.51 | +244.03% | 14 | Nov 13, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Sector Perform | $5 → $4 | $1.84 | +117.39% | 1 | Nov 11, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $49 → $50 | $23.75 | +110.53% | 15 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Outperform | $18 → $19 | $14.92 | +27.35% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $44 | $35.20 | +25.00% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $155 | $173.15 | -10.48% | 2 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $19 → $9 | $10.84 | -16.97% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $8.58 | -6.76% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $189 → $198 | $178.69 | +10.81% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $77 | $79.02 | -2.56% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $27 → $11 | $6.68 | +64.67% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $47 | $28.26 | +66.31% | 5 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $45 | $43.58 | +3.26% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $12.16 | +80.92% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $33.85 | +21.12% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $7.23 | +79.81% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.52 | +42.05% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $2.79 | +473.48% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.12 | +167.86% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $101.42 | -30.98% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $6.55 | +174.81% | 4 | Jan 15, 2025 |
Cytokinetics
Dec 22, 2025
Maintains: Outperform
Price Target: $87 → $95
Current: $61.73
Upside: +53.90%
Pyxis Oncology
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.15
Upside: +334.78%
Insmed
Dec 18, 2025
Maintains: Outperform
Price Target: $215 → $195
Current: $177.12
Upside: +10.09%
Design Therapeutics
Nov 20, 2025
Upgrades: Outperform
Price Target: $6 → $13
Current: $9.09
Upside: +43.01%
BeOne Medicines AG
Nov 18, 2025
Maintains: Outperform
Price Target: $395 → $408
Current: $311.02
Upside: +31.18%
CG Oncology
Nov 17, 2025
Maintains: Outperform
Price Target: $53 → $61
Current: $41.79
Upside: +45.97%
Legend Biotech
Nov 13, 2025
Maintains: Outperform
Price Target: $75 → $74
Current: $21.51
Upside: +244.03%
Jasper Therapeutics
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.84
Upside: +117.39%
Edgewise Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $23.75
Upside: +110.53%
Xencor
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $14.92
Upside: +27.35%
Nov 6, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $35.20
Upside: +25.00%
Nov 6, 2025
Maintains: Outperform
Price Target: $151 → $155
Current: $173.15
Upside: -10.48%
Nov 6, 2025
Maintains: Sector Perform
Price Target: $19 → $9
Current: $10.84
Upside: -16.97%
Nov 4, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $8.58
Upside: -6.76%
Nov 4, 2025
Maintains: Outperform
Price Target: $189 → $198
Current: $178.69
Upside: +10.81%
Nov 3, 2025
Initiates: Outperform
Price Target: $77
Current: $79.02
Upside: -2.56%
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $6.68
Upside: +64.67%
Oct 23, 2025
Maintains: Outperform
Price Target: $45 → $47
Current: $28.26
Upside: +66.31%
Oct 21, 2025
Reiterates: Sector Perform
Price Target: $45
Current: $43.58
Upside: +3.26%
Oct 21, 2025
Maintains: Outperform
Price Target: $21 → $22
Current: $12.16
Upside: +80.92%
Oct 21, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $33.85
Upside: +21.12%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $7.23
Upside: +79.81%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.52
Upside: +42.05%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $2.79
Upside: +473.48%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.12
Upside: +167.86%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $101.42
Upside: -30.98%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $6.55
Upside: +174.81%